scholarly journals Economic Impact of Infected Total Knee Arthroplasty

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Maximilian Haenle ◽  
Christina Skripitz ◽  
Wolfram Mittelmeier ◽  
Ralf Skripitz

Background.An enormous economic impact can be observed for infected total knee arthroplasties (TKA). The aim of the present study was to evaluate whether a cost covering treatment of infected TKA is feasible in the German DRG System.Patients and Methods.Average total treatment costs were evaluated for infected TKA and compared with a matched pair of primary TKA. Data was generated using the health record and the hospitals’ health information system. Results were evaluated and compared regarding the total personnel and material costs with respect to the financial receipts.Results.A total of 28 patients diagnosed with an infected TKA were included. A significant increase in the average length of stay, use of medical supplies and third party medical examinations were found for the infected TKA. An average deficiency of 6,356€ per patient was observed for the infected TKA. An average profit of 927€ per patient was made performing primary TKA.Conclusions.A cost-effective treatment of infected TKA was not feasible with the receipts from the German DRG System. An adaption of the receipts has to be evaluated. Moreover, other measures have to be considered in order to achieve a comprehensive medical yet financial reasonable standard in the treatment of infected TKA and THA.

Author(s):  
Blair S. Ashley ◽  
Javad Parvizi

AbstractTotal knee arthroplasty is a widely successful procedure, but a small percentage of patients have a postoperative course complicated by periprosthetic joint infection (PJI). PJI is a difficult problem to diagnose and to treat, and the management of PJI differs, depending on the acuity of the infection. This paper discusses the established and newer technologies developed for the diagnosis of PJI as well as different treatment considerations and surgical solutions currently available.


2012 ◽  
Vol 27 (2) ◽  
pp. 253-259.e4 ◽  
Author(s):  
Suhel Y. Kotwal ◽  
Yasser R. Farid ◽  
Suresh S. Patil ◽  
Kris J. Alden ◽  
Henry A. Finn

2009 ◽  
Vol 24 (4) ◽  
pp. 631-635 ◽  
Author(s):  
John A. Anderson ◽  
Peter K. Sculco ◽  
Sven Heitkemper ◽  
David J. Mayman ◽  
Mathias P. Bostrom ◽  
...  

2018 ◽  
Vol 32 (10) ◽  
pp. 953-959 ◽  
Author(s):  
Felix Greimel ◽  
Günther Maderbacher ◽  
Clemens Baier ◽  
Timo Schwarz ◽  
Florian Zeman ◽  
...  

AbstractIn the recent past, numerous studies evaluating local infiltration analgesia (LIA) with controversial results have been reported. Efforts have been made to improve patients' outcome regarding operation techniques and material, as well as pain management and anesthetic methods. In this study, postoperative pain management and patient satisfaction were evaluated in patients undergoing total knee replacement surgery with or without intraoperative LIA. Within the context of the “Quality Improvement in Postoperative Pain Management” (QUIPS) project, parameters were collected on the first postoperative day. All patients included in this study underwent primary knee replacement surgery with general anesthesia. Parameters were compared after performing a 1:1 matched-pair analysis within 14 orthopaedic departments. Pain levels and pain management satisfaction were measured using the numerous rating scales, and pain medication use was compared. From 2010 to 2015, 2,789 patients who underwent primary knee arthroplasty with general anesthesia were evaluated within the project, of whom a total of 846 patients could be compared after performing a matched-pair analysis. Pain scores were significantly better in the LIA group (p = 0.019 for activity pain, p = 0.043 for maximum pain, p < 0.001 for minimum pain), but pain management satisfaction was not superior (p = 0.083). Patients with LIA required less opioids in the recovery room (p = 0.048), while nonopioid medication did not differ significantly (p = 0.603). At the ward, 24 hours postoperatively, no significant difference in the use for nonopioids (p = 0.789) could be measured, whereas patients in the LIA group received significantly more opioids (p < 0.001). Although LIA achieved improvement in pain score outcome, and a comparable patient satisfaction level in the immediate postoperative course, the use of LIA in knee arthroplasty, controversially discussed in the current literature, was not able to reduce the need for opioid pain medication in this study.


Author(s):  
J.M. Durand ◽  
P. Viale ◽  
P. Massin ◽  
J.L. Cotte ◽  
C. Jardin

The Rolflex TONIC total knee implant was launched in early 2016. It is a cruciate sacrificing design and offers a choice of 2 cruciate substituting mechanism according to the UC (Ultra-Congruent) concept or to the PS (Postero-stabilisation with peg and cam) concept. The PS choice can be associated to a fixed tibial bearing or to a mobile tibial bearing, while the UC choice can only be associated to a mobile tibial bearing. The international use of UC total knee prosthesis is low: according to the 2019 AJRR report the UC variant was up at 4.5% of use in 2018, while the PS variant accounted for the largest frequency of use at 51.6%. The second most used type of TKA was the cruciate retaining (CR) variant at 43.8% of use. There is currently no CR variant in the Rolflex TONIC portfolio. In order to inform of any differences in terms of etiology, indications, patient profile, surgical choices, and clinical and functional performance between the PS and the UC cruciate substituting mechanisms, this document will analyze only the mobile bearing variants of the Roflex TONIC UC and PS. The patients implanted with Fixed bearing PS will not be included in this analysis. A prospective clinical follow-up of the Rolflex TONIC has been organized by the sponsor (Evolutis, Briennon, France) to evaluate the safety and performance of this new device. This study includes the implants used since June 2016 and up to December 2018. The study design will review the patients at 2, 5 and 10 years of follow-up. At the date of this intermediary report, the 2 years review is not yet terminated. The 2 years report is expected for early 2021 when all patients included will show more than 2 years of FU. Therefore, this intermediary analysis should only be viewed as a security control analysis in search for any anticipated deviation in the expected results. The average length of follow- up will remain short until all patients will be reviewed at 2 years of minimal FU, yet it will evidence if any short or mid-term complication occurred, and how good is the recovery of the patients estimated through an IKS and an OXFORD scores.


2005 ◽  
Vol 54 (1) ◽  
pp. 72-76
Author(s):  
Masanori Kawano ◽  
Mitsuru Sakaguchi ◽  
Kei Hirakawa ◽  
Kenichi Yawatari ◽  
Takayuki Iwanaga ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document